Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,764Revenue $M64.5Net Margin (%)16.9Altman Z-Score2.3
Enterprise Value $M1,782EPS $0.6Operating Margin %28.3Piotroski F-Score7
P/E(ttm)176Beneish M-Score-3.5Pre-tax Margin (%)14.4Higher ROA y-yN
Price/Book52.810-y EBITDA Growth Rate %--Quick Ratio10.4Cash flow > EarningsY
Price/Sales29.95-y EBITDA Growth Rate %--Current Ratio10.6Lower Leverage y-yN
Price/Free Cash Flow111y-y EBITDA Growth Rate %9.0ROA % (ttm)5.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)22.7Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M19.7ROIC % (ttm)34.5Gross Margin Increase y-yY

Gurus Latest Trades with LGND

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LGNDJoel Greenblatt 2015-03-31 Sold Out -0.0016%$51.54 - $77.11
($61.42)
$ 89.6746%Sold Out0
LGNDJoel Greenblatt 2014-12-31 Reduce-0.26%$42.36 - $57.96
($52.25)
$ 89.6772%Reduce 99.32%3,766
LGNDKen Fisher 2014-12-31 Add0.01%$42.36 - $57.96
($52.23)
$ 89.6772%Add 132.31%81,908
LGNDJoel Greenblatt 2014-09-30 Add0.23%$46.99 - $64.52
($53.04)
$ 89.6769%Add 894.83%552,053
LGNDJoel Greenblatt 2014-06-30 Buy 0.04%$59.74 - $70.19
($65.09)
$ 89.6738%New holding55,492
LGNDKen Fisher 2014-06-30 Buy $59.74 - $70.19
($65.09)
$ 89.6738%New holding36,908
LGNDJoel Greenblatt 2014-03-31 Sold Out -0.02%$51.52 - $79.58
($66.37)
$ 89.6735%Sold Out0
LGNDJoel Greenblatt 2013-12-31 Add0.01%$44.86 - $57.95
($52.33)
$ 89.6771%Add 124.95%13,803
LGNDJoel Greenblatt 2013-09-30 Buy 0.01%$38.69 - $49.66
($45.21)
$ 89.6798%New holding6,136
LGNDGeorge Soros 2011-09-30 Sold Out -0.0017%$10.89 - $15.95
($13.18)
$ 89.67580%Sold Out0
LGNDGeorge Soros 2011-06-30 Buy $9.56 - $12.02
($10.55)
$ 89.67750%New holding10,000
LGNDGeorge Soros 2009-12-31 Sold Out $9.96 - $14.16
($12.14)
$ 89.67639%Sold Out0
LGNDGeorge Soros 2009-09-30 Buy $13.74 - $18.9
($16.16)
$ 89.67455%New holding4,483
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LGND is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


LGND: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Aryeh JasonDirector 2015-05-20Sell9,240$87.342.67view
DeSilva Nishan MVP, Finance & Strategy and CFO 2015-05-14Sell68,363$83.916.86view
Patel SunilDirector 2015-03-19Sell4,591$74.4220.49view
Berkman Charles SVP, Gen. Counsel & Secretary 2015-03-16Sell11,264$74.5420.3view
Herman Melanie JDirector of Accounting 2015-03-02Sell535$60.6947.75view
Herman Melanie JDirector of Accounting 2015-02-19Sell510$57.8455.03view
DeSilva Nishan MVP, Corporate Development 2015-02-10Sell2,300$56.3459.16view
Berkman Charles SVP, Gen. Counsel & Secretary 2014-12-31Buy126$45.2398.25view
FOEHR MATTHEW WEVP and COO 2014-12-31Buy46$45.2398.25view
Herman Melanie JDirector of Accounting 2014-12-31Buy103$45.2398.25view

Press Releases about LGND :

Quarterly/Annual Reports about LGND:

News about LGND:

Articles On GuruFocus.com
dick Feb 13 2015 
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand to Acquire Neurogen for Stock and Contingent Value Rights Aug 24 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 
Ligand Pharmaceuticals Announces Second Quarter Results Aug 03 2009 
Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results Feb 12 2009 

More From Other Websites
LIGAND PHARMACEUTICALS INC Financials May 19 2015
10-Q for Ligand Pharmaceuticals, Inc. May 14 2015
Ligand Pharmaceuticals Tops Q1 Earnings, Affirms View - Analyst Blog May 12 2015
Company News for May 12, 2015 - Corporate Summary May 12 2015
Actavis Earnings Strong, Gives 2015 Guidance May 11 2015
Ligand Acquires Rights to More Than 15 Fully-Funded Development Programs from Selexis SA May 11 2015
Ligand Reports First Quarter 2015 Financial Results May 11 2015
Ligand Pharmaceuticals (LGND) Beats on Q1 Earnings - Tale of the Tape May 11 2015
Ligand tops Street 1Q forecasts May 11 2015
Ligand tops Street 1Q forecasts May 11 2015
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Results... May 11 2015
Ligand Reports First Quarter 2015 Financial Results May 11 2015
Ligand Acquires Rights to More Than 15 Fully-Funded Development Programs from Selexis SA May 11 2015
Q1 2015 Ligand Pharmaceuticals Inc Earnings Release - Before Market Open May 11 2015
Q1 Earnings Drive Industry Group Winners And Losers May 08 2015
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Triggering Events That Accelerate or Increase a... May 08 2015
Will Ligand Pharmaceuticals (LGND) Miss on Q1 Earnings? - Analyst Blog May 07 2015
Ligand to Present Results of LGD-6972 Phase 1b Trial at American Diabetes Association 75th... May 07 2015
Ligand to Present Results of LGD-6972 Phase 1b Trial at American Diabetes Association 75th... May 07 2015
Ligand Partner Viking Therapeutics Announces Closing of Initial Public Offering May 05 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK